trending Market Intelligence /marketintelligence/en/news-insights/trending/dDtpmzo6Qov4lSyMRq2ymQ2 content esgSubNav
In This List

Report: Teva plans to sell Israeli plant to Germany's B. Braun Melsungen

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Report: Teva plans to sell Israeli plant to Germany's B. Braun Melsungen

Teva Pharmaceutical Industries Ltd is nearing a sale of its manufacturing site at Kiryat Shmona in Israel to German company B. Braun Melsungen AG, FiercePharma reported Oct. 10, citing Israeli newspaper Calcalist.

The plant, that makes plastic products for the pharmaceutical industry, employees about 200 people and could fetch the Israeli drugmaker up to $100 million, the head of the plant's union committee told the Israeli newspaper.

Teva Pharmaceutical said in December 2017 that it will cut 14,000 jobs globally to reduce costs of up to $3 billion by the end of 2019.

Of the 14,000 jobs, 1,750 positions are expected to be eliminated in Israel, the news outlet reported, adding that Teva declined to comment on the matter.